Shionogi &
Shionogi & Co Ltd is a Japanese pharmaceutical enterprise engaged in the research, development, manufacturing, and marketing of prescription medicines and diagnostic reagents. The company's primary therapeutic focus areas comprise infectious diseases, central nervous system disorders, and pain management solutions. Revenue is driven by domestic sales of prescription pharmaceuticals in Japan alongside substantial international royalty income from licensed HIV therapies like dolutegravir. Target end markets include retail pharmacies, hospital networks, government healthcare programs, and medical practitioners globally. Shionogi holds a leading position among Japanese biopharmaceutical companies, recognized particularly for its anti-infective and antiviral drug discovery pipeline. The company is headquartered in Osaka, Japan, and its common shares trade on the Tokyo Stock Exchange under the ticker symbol 4507.
48 of the funds FundTelligence covers report a position in Shionogi &.
- Legal name
- Shionogi & Co Ltd
- Sector
- Health Care
- Country
- Japan
- Funds holding it
- 48
Funds holding Shionogi &
- DWS Invest CROCI Japan — DWS · 3.24 % (full portfolio disclosed, June 2026)
- DWS Invest CROCI Sectors Plus — DWS · 3.08 % (full portfolio disclosed, June 2026)
- Fondsfinans Global Helse — Fondsfinans · 1.83 % (full portfolio disclosed, October 2026)
- DWS Invest CROCI Global Dividends — DWS · 1.8 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 1.28 % (full portfolio disclosed, October 2026)
- DWS Invest CROCI World Value — DWS · 0.98 % (full portfolio disclosed, June 2026)
- Handelsbanken Infrastruktur och Beredskap — Handelsbanken · 0.69 % (full portfolio disclosed, October 2026)
- Danske Invest Japan Index Restricted — Danske Invest · 0.58 % (full portfolio disclosed, July 2026)
Showing the 8 largest of 48 funds holding it.